Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective double-blind randomised placebo-controlled repeated cross-over trial evaluating the efficacy, acceptability, safety and tolerability of Wafermine administered as a first-line treatment for patients with advanced cancer suffering from moderate to severe pain

Next Previous
X
Search
Trial Profile

A prospective double-blind randomised placebo-controlled repeated cross-over trial evaluating the efficacy, acceptability, safety and tolerability of Wafermine administered as a first-line treatment for patients with advanced cancer suffering from moderate to severe pain

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ketamine (Primary)
  • Indications Pain
  • Focus Therapeutic Use

    • Most Recent Events

    • 22 Jun 2021 New trial record
    • 15 Jun 2021 According to an IX BIOPHARMA media release, the results of this study will assist in the conduct of a definitive trial in guiding physicians on the use of Wafermine to treat cancer pain
    • 15 Jun 2021 According to an IX BIOPHARMA media release, this study will be led by Dr Yi-Ching Lee, Consultant Pain Specialist in Chris OBrien Lifehouse & Royal Prince Alfred Hospital.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top